Company intelligence / Profile preview

Shanghai Sinobioway Sunterra Biotechnology

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Ethics committee approval received for two novel CAB-CAR-T candidates targeting Axl and Ror2 in metastatic renal cell carcinoma. These are among the first tumor microenvironment-controlled CAR-T products in China, launched in collaboration with top Chinese hospitals. No reported clinical results yet, as trials were recently approved.

Therapeutic areas: Oncology
Modalities: CAR-T cell therapyConditionally Active BiologicsAdoptive cellular therapy
Industry: Biotech

Partnerships

F1 Oncology (clinical development, technology licensing)Sunterra Capital (founding/investor)BioAtla (CAB technology collaboration)

Beyond the preview

Go deeper on Shanghai Sinobioway Sunterra Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Sinobioway Sunterra Biotechnology.

Explore the full profile